We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$3.33M
Cap. Flow
-$9.09M
Cap. Flow %
-4.16%
Top 10 Hldgs %
53.49%
Holding
80
New
23
Increased
12
Reduced
26
Closed
8
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
RDUS icon
Radius Health, Inc.
RDUS
+$4.26M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$3.77M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.35M
4
SAGE icon
Sage Therapeutics
SAGE
+$3.05M
5
SNY icon
Sanofi
SNY
+$2.95M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$9.92M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.66M
3
ENSG icon
The Ensign Group
ENSG
+$5.27M
4
ARRY icon
Array Biopharma Inc
ARRY
+$4.92M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.72M

Sector Composition

Rank Sector Weight
1 Healthcare 72.69%
2 Real Estate 11.35%
3 Industrials 8.34%
4 Miscellaneous 6.63%
5 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARGX icon
26
argenx
ARGX
$51.5B
$2.02M 0.92%
24,384
-11,400
-32% -$1.02M
2017 Q4
2 quarters
ASND icon
27
Ascendis Pharma A/S
ASND
$14.8B
$2M 0.91%
30,054
+6,000
+25% +$395K
2017 Q4
2 quarters
IVC
28
DELISTED
Invacare Corporation
IVC
$1.86M 0.85%
99,902
– –
2017 Q4
2 quarters
CTRE icon
29
CareTrust REIT
CTRE
$8.6B
$1.71M 0.78%
101,264
-7,000
-6% -$105K
2017 Q4
2 quarters
MDCO
30
DELISTED
Medicines Co
MDCO
$1.44M 0.66%
39,317
– –
2018 Q1
1 quarter
CBAY icon
31
DELISTED
Cymabay Therapeutics
CBAY
$1.44M 0.66%
+107,096
New +$1.34M
2018 Q2
0 quarters
AMRN icon
32
Amarin Corp
AMRN
$238M
$1.42M 0.65%
23,000
+10,500
+84% +$650K
2018 Q1
1 quarter
PBYI icon
33
Puma Biotechnology
PBYI
$512M
$1.42M 0.65%
23,924
+1,000
+4% +$58K
2017 Q4
2 quarters
TNDM icon
34
Tandem Diabetes Care
TNDM
$1.15B
$1.35M 0.62%
+61,300
New +$754K
2018 Q2
0 quarters
HAE icon
35
Haemonetics
HAE
$5.42B
$1.31M 0.6%
14,646
– –
2018 Q1
1 quarter
IMMU
36
DELISTED
Immunomedics Inc
IMMU
$1.3M 0.6%
+55,000
New +$1.11M
2018 Q2
0 quarters
MYOK
37
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.29M 0.59%
25,950
-16,050
-38% -$777K
2017 Q4
2 quarters
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$10.5B
$1.26M 0.58%
+4,500
New +$790K
2018 Q2
0 quarters
EHTH icon
39
eHealth
EHTH
$18.6M
$1.25M 0.57%
56,546
-18,000
-24% -$347K
2017 Q4
2 quarters
ELV icon
40
Elevance Health
ELV
$93.2B
$1.19M 0.54%
5,000
-1,000
-17% -$232K
2018 Q1
1 quarter
AKRX
41
DELISTED
Akorn Inc
AKRX
$1.16M 0.53%
+70,000
New +$1.07M
2018 Q2
0 quarters
TGTX icon
42
TG Therapeutics
TGTX
$8.29B
$1.05M 0.48%
80,000
-70,000
-47% -$963K
2018 Q1
1 quarter
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.04M 0.48%
+85,000
New +$1.07M
2018 Q2
0 quarters
CNC icon
44
Centene
CNC
$34.3B
$986K 0.45%
16,000
-4,000
-20% -$231K
2018 Q1
1 quarter
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$1.99B
$854K 0.39%
148,959
– –
2017 Q4
2 quarters
CLLS icon
46
Cellectis
CLLS
$106M
$849K 0.39%
+30,000
New +$893K
2018 Q2
0 quarters
ARRY icon
47
DELISTED
Array Biopharma Inc
ARRY
$812K 0.37%
48,412
-309,315
-86% -$4.92M
2017 Q4
2 quarters
VCEL icon
48
Vericel Corp
VCEL
$2.05B
$726K 0.33%
+74,837
New +$932K
2018 Q2
0 quarters
ABUS icon
49
Arbutus Biopharma
ABUS
$842M
$712K 0.33%
97,495
-20,000
-17% -$119K
2017 Q4
2 quarters
IOVA icon
50
Iovance Biotherapeutics
IOVA
$6.23B
$704K 0.32%
55,000
-10,000
-15% -$146K
2018 Q1
1 quarter
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Eversept Partners held 80 positions worth $219M, up 1.5% from $215M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners withdrew a net $9.09M in Q2 2018, closing 8 positions and reducing 26 holdings. Its most notable exit was Ablynx NV, an estimated $9.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 75% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Eversept Partners opened a new position in Sarepta Therapeutics worth $5.29M.

  • Eversept Partners's largest Q2 2018 buy was Sarepta Therapeutics: 40,000 shares worth $5.29M.
  • Eversept Partners added most to Radius Health, Inc. in Q2 2018, an estimated $4.26M increase.
  • Eversept Partners's biggest Q2 2018 reduction was The Ensign Group, cutting an estimated $5.27M.
  • Eversept Partners fully exited Ablynx NV in Q2 2018, selling an estimated $9.92M.
  • Eversept Partners's ten largest holdings make up 53% of its $219M portfolio in Q2 2018.
  • Eversept Partners opened 23 new positions and closed 8 in Q2 2018.
  • Eversept Partners's portfolio value rose 1.5% quarter-over-quarter to $219M.

Based on Eversept Partners's 13F filing for Q2 2018, filed 14 Aug 2018.